Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | JAK2 |
| Variant | Y931C |
| Impact List | missense |
| Protein Effect | gain of function |
| Gene Variant Descriptions | JAK2 Y931C lies within the protein kinase domain 2 of the Jak2 protein (UniProt.org). Y931C results in increased phosphorylation of Jak2 and Stat5, is transforming in cell culture, and confers resistance to Jak inhibitors (PMID: 21393331, PMID: 26419724). |
| Associated Drug Resistance | Y |
| Category Variants Paths |
JAK2 mutant JAK2 act mut JAK2 Y931C |
| Transcript | NM_004972.4 |
| gDNA | chr9:g.5090476A>G |
| cDNA | c.2792A>G |
| Protein | p.Y931C |
| Source Database | RefSeq |
| Genome Build | GRCh38/hg38 |
| Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
|---|---|---|---|---|---|
| NM_004972.3 | chr9:g.5090476A>G | c.2792A>G | p.Y931C | RefSeq | GRCh38/hg38 |
| NM_001322196.2 | chr9:g.5090476A>G | c.2792A>G | p.Y931C | RefSeq | GRCh38/hg38 |
| NM_001322194.2 | chr9:g.5090476A>G | c.2792A>G | p.Y931C | RefSeq | GRCh38/hg38 |
| NM_001322194.1 | chr9:g.5090476A>G | c.2792A>G | p.Y931C | RefSeq | GRCh38/hg38 |
| NM_001322196.1 | chr9:g.5090476A>G | c.2792A>G | p.Y931C | RefSeq | GRCh38/hg38 |
| NM_004972.4 | chr9:g.5090476A>G | c.2792A>G | p.Y931C | RefSeq | GRCh38/hg38 |
| NM_001322195.1 | chr9:g.5090476A>G | c.2792A>G | p.Y931C | RefSeq | GRCh38/hg38 |
| NM_001322196 | chr9:g.5090476A>G | c.2792A>G | p.Y931C | RefSeq | GRCh38/hg38 |
| NM_001322195.2 | chr9:g.5090476A>G | c.2792A>G | p.Y931C | RefSeq | GRCh38/hg38 |
| NM_001322194 | chr9:g.5090476A>G | c.2792A>G | p.Y931C | RefSeq | GRCh38/hg38 |
| NM_001322195 | chr9:g.5090476A>G | c.2792A>G | p.Y931C | RefSeq | GRCh38/hg38 |
| NM_004972 | chr9:g.5090476A>G | c.2792A>G | p.Y931C | RefSeq | GRCh38/hg38 |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05745714 | Phase Ib/II | Cyclophosphamide + Cytarabine + Dexamethasone + Ruxolitinib + Venetoclax | HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies (HEM-iSMART C) | Recruiting | SWE | NOR | NLD | ITA | ISR | IRL | GBR | FRA | FIN | ESP | DNK | DEU | BEL | AUT | 0 |